Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Among the large drugmakers, Eli Lilly, AstraZeneca AZN, Pfizer PFE, Sanofi SNY and Bayer BAYRY are worth retaining ... at U ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. The grant comes from the ...

“Sanofi is a global leader in immunological ... research and preclinical and clinical testing; disruptions in the supply chain, including raw materials needed for manufacturing and animals ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...

The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

The latest award from the government, which includes $37.9 million for CSL, $23.4 million for Sanofi and $10.5 million for GSK, would more than double the United States' supply of shots targeting ...